Volume 31, Issue 6 (September 2020)                   Stud Med Sci 2020, 31(6): 485-498 | Back to browse issues page

XML Persian Abstract Print


Department of Microbiology, Faculty of veterinary medicine, University of Urmia, Urmia, Iran , afsharnegin92@gmail.com
Abstract:   (934 Views)
Background & Aims: Recent studies have demonstrated an important role for Th-17 lymphocytes and other cytokines in pathogenesis of multiple sclerosis. Although previous studies have demonstrated the anti-inflammatory potential of troxerutin,  the effects of troxerutin on multiple sclerosis have not been studied so far. The present study was carried out to investigate the therapeutic effects of troxerutin on experimental autoimmune encephalomyelitis (EAE) by reducing the production of pro-inflammatory cytokines IL-17, IL-1, TNF-α, and reducing nitric oxide levels and reducing immune cell proliferation.
Materials & Methods: EAE was induced by MOG35-55 peptide and complete Freund's adjuvant in female C57BL/6 mice. The mice were placed in four therapeutic groups of 5. Treatment with troxerutin (135 mg/kg daily) was started in the treatment group when they developed a disability score. Signs of disease were recorded daily until the day 21 when mice were sacrificed. Then, Immune cells were tested to assess proliferation rate, cytokine, and nitric oxide by the 3-(4,5 dimethylthiozol-2-yl)-2,5- diphenyl-tetrazolium bromide (MTT) assay, enzyme-linked immunosorbent assay (ELISA), and Greiss, respectively.
Results: The troxerutin significantly decreased the clinical signs of established EAE. Troxerutin significantly decreased the production of pro-inflammatory cytokines IL-17, IL-1 TNF-α and decreased levels of nitric oxide, while reduced the proliferation of immune cells (p<0.05).
Conclusion: Parallel with decreasing proliferation of Immune cells and cytokine production, troxerutin ameliorated established EAE.
Full-Text [PDF 3264 kb]   (232 Downloads)    
Type of Study: Research | Subject: ایمونولوژی

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.